Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236266 | 0.96 | PREP (0.40) | PREPFFAR1TPH1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7236572 | 0.95 | PREP (0.39) | PREPFFAR1TPH1KMT2ASMN1; SMN2 | |
| SCHEMBL7237737 | 0.83 | PREP (0.41) | PREPKMT2ACA12CA1CA9 | |
| SCHEMBL7455145 | 0.83 | PREP (0.41) | PREPKMT2ACA12CA1CA9 | |
| SCHEMBL7236135 | 0.82 | PREP (0.40) | PREP | |
| SCHEMBL10317188 | 0.81 | PREP (0.41) | PREPFFAR1KMT2ASMN1; SMN2CA12 | |
| SCHEMBL5624168 | 0.81 | KDM4E (0.40) | PREPCA12CA1CA9 | |
| SCHEMBL5624172 | 0.81 | KDM4E (0.40) | PREPCA12CA1CA9 | |
| SCHEMBL10317583 | 0.76 | FFAR1 (0.55) | FFAR1 | |
| SCHEMBL27582399 | 0.76 | KMT2A (0.43) | FFAR1TPH1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |